AI Engines For more Details: Perplexity Kagi Labs You
Benign Prostatic Hyperplasia (BPH): Naftopidil dihydrochloride is an alpha-1 adrenergic receptor antagonist. It works by relaxing the smooth muscles in the prostate gland and the bladder neck, improving urinary flow and reducing symptoms associated with BPH, such as urinary frequency, urgency, nocturia, weak urine stream, and incomplete bladder emptying.
Lower Urinary Tract Symptoms (LUTS): Naftopidil is effective in alleviating lower urinary tract symptoms commonly associated with BPH, including urinary hesitancy, straining, and the sensation of incomplete bladder emptying. By reducing bladder outlet obstruction, it helps improve urinary function and overall quality of life in patients with BPH.
Improvement in Urodynamic Parameters: Naftopidil has been shown to improve urodynamic parameters such as maximum urinary flow rate (Qmax), detrusor pressure at maximum flow (PdetQmax), and bladder capacity. These improvements contribute to better bladder emptying and reduced urinary symptoms in patients with BPH.
Efficacy Compared to Other Alpha Blockers: Clinical studies have demonstrated the efficacy of naftopidil in improving lower urinary tract symptoms in patients with BPH. It has been found to be comparable to other alpha-1 blockers such as tamsulosin and alfuzosin in terms of symptom relief and improvement in urodynamic parameters.
Safety Profile: Naftopidil is generally well-tolerated, with most adverse effects being mild to moderate in severity. Common side effects may include dizziness, headache, orthostatic hypotension (low blood pressure upon standing), fatigue, and gastrointestinal disturbances such as nausea and constipation. These side effects are usually transient and resolve with continued use or dose adjustment.
Contraindications and Precautions: Naftopidil should be used with caution in patients with severe hepatic impairment or renal impairment, as dosage adjustments may be necessary due to altered drug metabolism and elimination. It should also be used cautiously in patients taking other medications that may potentiate its hypotensive effects or affect hepatic metabolism.
Drug Interactions: Naftopidil may interact with medications that lower blood pressure or affect cardiac conduction, such as antihypertensive agents, vasodilators, and drugs that prolong the QT interval. Concurrent use of these medications may increase the risk of hypotension or cardiac arrhythmias and should be monitored closely.
Monitoring: Patients receiving naftopidil therapy should be monitored regularly for changes in blood pressure, especially during the initial titration phase and after dose adjustments. It is important to educate patients about the signs and symptoms of hypotension and orthostatic hypotension to prevent falls and other adverse events.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 1 | 1 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.2 | 0.6 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 2.5 | 1.4 | 0.79 |
| Allergies | 5.2 | 3.5 | 0.49 |
| Allergy to milk products | 2.1 | 1.6 | 0.31 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 5.2 | 4.4 | 0.18 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 1 | 2.2 |
| Ankylosing spondylitis | 3.4 | 1.8 | 0.89 |
| Anorexia Nervosa | 1.4 | 1.9 | -0.36 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.3 | 1.67 |
| Asthma | 3.3 | 1.8 | 0.83 |
| Atherosclerosis | 1.7 | 0.7 | 1.43 |
| Atrial fibrillation | 2.8 | 3.1 | -0.11 |
| Autism | 8.9 | 8.3 | 0.07 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 2.4 | 1.2 | 1 |
| Brain Trauma | 0.6 | 0.9 | -0.5 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.9 | 1.4 | -0.56 |
| Carcinoma | 3.5 | 2 | 0.75 |
| Celiac Disease | 1.7 | 3.6 | -1.12 |
| Cerebral Palsy | 1.4 | 0.7 | 1 |
| Chronic Fatigue Syndrome | 5 | 4.2 | 0.19 |
| Chronic Kidney Disease | 3.5 | 2.4 | 0.46 |
| Chronic Lyme | 0.4 | 0.3 | 0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.2 | -0.2 |
| Chronic Urticaria (Hives) | 1.2 | 1.4 | -0.17 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 0.4 | 1.75 |
| Cognitive Function | 2.2 | 0.8 | 1.75 |
| Colorectal Cancer | 5.2 | 1.8 | 1.89 |
| Constipation | 2 | 0.1 | 19 |
| Coronary artery disease | 2.2 | 2 | 0.1 |
| COVID-19 | 7.9 | 8.9 | -0.13 |
| Crohn's Disease | 6.7 | 5.2 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.7 | 0.7 | 0 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 1.5 | 0.6 | 1.5 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 8.3 | 7.2 | 0.15 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 2 | 0.6 | 2.33 |
| Endometriosis | 2.1 | 1.6 | 0.31 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.9 | 2.2 | 0.32 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 1.5 | 2.5 | -0.67 |
| Functional constipation / chronic idiopathic constipation | 4.6 | 3 | 0.53 |
| gallstone disease (gsd) | 2.8 | 0.9 | 2.11 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.9 | 0.44 |
| Generalized anxiety disorder | 2.9 | 2 | 0.45 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1 | 0.8 | 0.25 |
| Graves' disease | 1.9 | 1.9 | 0 |
| Gulf War Syndrome | 0.6 | 2.1 | -2.5 |
| Halitosis | 0.9 | 0.9 | |
| Hashimoto's thyroiditis | 2.4 | 1.8 | 0.33 |
| Heart Failure | 3.9 | 1.7 | 1.29 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 1.5 | 2.1 | -0.4 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.9 | 4.3 | -0.1 |
| Hypothyroidism | 0.4 | 1 | -1.5 |
| Hypoxia | 2.7 | 0.3 | 8 |
| IgA nephropathy (IgAN) | 1.6 | 4.1 | -1.56 |
| Inflammatory Bowel Disease | 6.2 | 7.5 | -0.21 |
| Insomnia | 1 | 2.5 | -1.5 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 5.3 | 4.9 | 0.08 |
| ischemic stroke | 2.4 | 1.2 | 1 |
| Liver Cirrhosis | 5.1 | 3.9 | 0.31 |
| Long COVID | 7.3 | 7 | 0.04 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.9 | -0.5 |
| ME/CFS with IBS | 0.8 | 1.8 | -1.25 |
| ME/CFS without IBS | 1.4 | 0.7 | 1 |
| Menopause | 0.8 | 0.4 | 1 |
| Metabolic Syndrome | 5.4 | 6.2 | -0.15 |
| Mood Disorders | 8.8 | 6.9 | 0.28 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 5.8 | 4.5 | 0.29 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| myasthenia gravis | 0.6 | 0.2 | 2 |
| neuropathic pain | 0.3 | 1.9 | -5.33 |
| Neuropathy (all types) | 0.8 | 1.2 | -0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 4.6 | -0.24 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 7.8 | 6.2 | 0.26 |
| obsessive-compulsive disorder | 5 | 3.7 | 0.35 |
| Osteoarthritis | 2.5 | 1.2 | 1.08 |
| Osteoporosis | 2 | 1 | 1 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 7.1 | 4.7 | 0.51 |
| Polycystic ovary syndrome | 5.5 | 2.7 | 1.04 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.3 | 1.3 | -3.33 |
| Primary sclerosing cholangitis | 1.7 | 2.7 | -0.59 |
| Psoriasis | 2 | 3 | -0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.4 | 3.1 | 1.06 |
| Rosacea | 0.9 | 0.2 | 3.5 |
| Schizophrenia | 6.3 | 2.9 | 1.17 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 2.5 | 1.9 | 0.32 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.6 | 1.5 |
| Stress / posttraumatic stress disorder | 2 | 2.5 | -0.25 |
| Systemic Lupus Erythematosus | 4.1 | 1.3 | 2.15 |
| Tic Disorder | 1.1 | 1.2 | -0.09 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 3.9 | 2.9 | 0.34 |
| Type 2 Diabetes | 6.9 | 5.8 | 0.19 |
| Ulcerative colitis | 3.9 | 6.4 | -0.64 |
| Unhealthy Ageing | 4.4 | 2.2 | 1 |
| Vitiligo | 1.8 | 1.9 | -0.06 |
